Conference Agenda

Schistosoma japonicum, the Asian schistosome, is a zoonotic parasite that infects humans and more than 40 species of domestic animals. It is a principal causative agent of schistosomiasis, a neglected tropical disease affecting 240 million people globally. In endemic regions, bovines are major reservoirs responsible for up to 75-90% of environmental egg contamination that perpetuate transmission. Current control efforts rely heavily on chemotherapy with Praziquantel, though effective at reducing worm burdens, does not prevent reinfection with risk of developing drug resistance if used solely. These limitations highlight the urgent need for integrated strategies to achieve sustainable control. Mathematical modelling has indicated that coupling chemotherapy with an effective transmission-blocking vaccine (TBV) could achieve elimination of S. japonicum within a decade. In this context, my PhD project seeks to develop an mRNA TBV by evaluating parasite-derived proteins with demonstrated immunogenicity and protective potential. Preliminary murine trials demonstrated significant reductions in worm and egg burdens, as well as alleviation of liver pathology. The integration of such promising antigens in a multivalent mRNA vaccine represents a rational strategy to maximize protection and durability of response and combined with control measures offers a promising pathway toward sustainable schistosomiasis control and improved global public health outcomes.